Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study
- PMID: 36202041
- PMCID: PMC9884995
- DOI: 10.1016/j.drugpo.2022.103853
Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study
Abstract
Background: The use of opioids is increasing globally, but data from low- and middle-income countries on opioid-related mental and behavioural disorders (hereafter referred to as opioid-related disorders) are scarce. This study examines the incidence of opioid-related disorders, opioid agonist use, and excess mortality among persons with opioid-related disorders in South Africa's private healthcare sector.
Methods: We analysed longitudinal data of beneficiaries (≥ 11 years) of a South African medical insurance scheme using reimbursement claims from Jan 1, 2011, to Jul 1, 2020. Beneficiaries were classified as having an opioid-related disorder if they received an opioid agonist (buprenorphine or methadone) or an ICD-10 diagnosis for harmful opioid use (F11.1), opioid dependence or withdrawal (F11.2-4), or an unspecified or other opioid-related disorder (F11.0, F11.5-9). We calculated adjusted hazard ratios (aHR) for factors associated with opioid-related disorders, estimated the cumulative incidence of opioid agonist use after receiving an ICD-10 diagnosis for opioid dependence or withdrawal, and examined excess mortality among beneficiaries with opioid-related disorders.
Results: Of 1,251,458 beneficiaries, 1286 (0.1%) had opioid-related disorders. Between 2011 and 2020, the incidence of opioid-related disorders increased by 12% (95% CI 9%-15%) per year. Men, young adults in their twenties, and beneficiaries with co-morbid mental health or other substance use disorders were at increased risk of opioid-related disorders. The cumulative incidence of opioid agonist use among beneficiaries who received an ICD-10 diagnosis for opioid dependence or withdrawal was 18.0% (95% CI 14.0-22.4) 3 years after diagnosis. After adjusting for age, sex, year, medical insurance coverage, and population group, opioid-related disorders were associated with an increased risk of mortality (aHR 2.28, 95% CI 1.84-2.82). Opioid-related disorders were associated with a 7.8-year shorter life expectancy.
Conclusions: The incidence of people diagnosed with or treated for an opioid-related disorder in the private sector is increasing rapidly. People with opioid-related disorders are a vulnerable population with substantial psychiatric comorbidity who often die prematurely. Evidence-based management of opioid-related disorders is urgently needed to improve the health outcomes of people with opioid-related disorders.
Keywords: Mortality; Opioid agonist therapy; Opioid substitution therapy; Opioid use disorders; Private sector; South Africa.
Copyright © 2022. Published by Elsevier B.V.
Conflict of interest statement
Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
Similar articles
-
Utilization of buprenorphine and methadone among opioid users who inject drugs.Subst Abus. 2018 Jan 2;39(1):83-88. doi: 10.1080/08897077.2017.1363844. Epub 2017 Sep 18. Subst Abus. 2018. PMID: 28796591 Free PMC article.
-
Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.Addiction. 2021 Mar;116(3):525-535. doi: 10.1111/add.15168. Epub 2020 Jul 14. Addiction. 2021. PMID: 32557931
-
Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.Addiction. 2023 Aug;118(8):1527-1539. doi: 10.1111/add.16178. Epub 2023 Mar 20. Addiction. 2023. PMID: 36843415 Free PMC article.
-
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.Hosp Pract (1995). 2022 Oct;50(4):251-258. doi: 10.1080/21548331.2022.2102776. Epub 2022 Jul 22. Hosp Pract (1995). 2022. PMID: 35837678 Review.
-
A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.Drug Alcohol Depend. 2019 Apr 1;197:168-182. doi: 10.1016/j.drugalcdep.2019.02.007. Epub 2019 Feb 15. Drug Alcohol Depend. 2019. PMID: 30831429
Cited by
-
Life-years lost associated with mental illness: a cohort study of beneficiaries of a South African medical insurance scheme.medRxiv [Preprint]. 2023 Feb 2:2023.01.19.23284778. doi: 10.1101/2023.01.19.23284778. medRxiv. 2023. Update in: J Affect Disord. 2023 Nov 1;340:204-212. doi: 10.1016/j.jad.2023.08.013. PMID: 36711937 Free PMC article. Updated. Preprint.
-
Mental Health, ART Adherence, and Viral Suppression Among Adolescents and Adults Living with HIV in South Africa: A Cohort Study.AIDS Behav. 2023 Jun;27(6):1849-1861. doi: 10.1007/s10461-022-03916-x. Epub 2023 Jan 2. AIDS Behav. 2023. PMID: 36592251 Free PMC article.
-
Evaluating client functioning in a harm reduction program in South Africa: insights from a tool derived from the International Classification of Functioning, Disability and Health.Front Rehabil Sci. 2024 Dec 19;5:1445176. doi: 10.3389/fresc.2024.1445176. eCollection 2024. Front Rehabil Sci. 2024. PMID: 39748831 Free PMC article.
-
Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses.Pharmacy (Basel). 2025 Mar 6;13(2):40. doi: 10.3390/pharmacy13020040. Pharmacy (Basel). 2025. PMID: 40126313 Free PMC article.
-
Life years lost associated with mental illness: A cohort study of beneficiaries of a South African medical insurance scheme.J Affect Disord. 2023 Nov 1;340:204-212. doi: 10.1016/j.jad.2023.08.013. Epub 2023 Aug 6. J Affect Disord. 2023. PMID: 37544483 Free PMC article.
References
-
- Abbafati C, Machado DB, Cislaghi B, Salman OM, Karanikolos M, McKee M, Abbas KM, Brady OJ, Larson HJ, Trias-Llimós S, Cummins S, Langan SM, Sartorius B, Hafiz A, Jenabi E, Mohammad Gholi Mezerji N, Borzouei S, Azarian G, Khazaei S, … Zhu C (2020a). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1204–1222. 10.1016/S0140-6736(20)30925-9 - DOI - PMC - PubMed
-
- Abbafati C, Machado DB, Cislaghi B, Salman OM, Karanikolos M, McKee M, Abbas KM, Brady OJ, Larson HJ, Trias-Llimós S, Cummins S, Langan SM, Sartorius B, Hafiz A, Jenabi E, Mohammad Gholi Mezerji N, Borzouei S, Azarian G, Khazaei S, … Zhu C (2020b). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 10.1016/S0140-6736(20)30752-2 - DOI - PMC - PubMed
-
- Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, Dabis F, Davies MA, Duda SN, Malateste K, Nash D, Wools-Kaloustian K, Von Groote PM, & Egger M (2020). International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012–2019. BMJ Open, 10(5). 10.1136/bmjopen-2019-035246 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous